Efficacy of ablation index-guided pulmonary vein isolation in patients with paroxysmal atrial fibrillation

Pacing Clin Electrophysiol. 2022 Oct;45(10):1186-1193. doi: 10.1111/pace.14578. Epub 2022 Sep 1.

Abstract

Background: Ablation index (AI) is a novel technology of ablation lesion quality to help improve homogeneity of lesion size and continuity. In this study, we aim to evaluate whether AI-guided PVI improves clinical outcomes compared to CF-guided PVI in patients with paroxysmal AF (PAF).

Methods: Patients undergoing first-time radiofrequency ablation for PAF were randomized in a 2:1 ratio to two groups: AI-guided PVI and CF-guided PVI. In the AI group, AI ≥500 was recommended at the anterior/superior/inferior walls, 350-400 at the posterior wall, and inter-lesion distance ≤4 mm. The primary endpoint is the freedom from atrial arrhythmia recurrence during 12 months follow-up, without antiarrhythmic drug therapy (ADT). The key secondary endpoints include intra-procedural efficiency and peri-procedural complications.

Results: Two hundred twenty five patients were randomized (AI group [n = 149] and CF group [n = 76]). First-pass isolation rate in AI group was significantly higher than that in CF group (58.3% vs. 43.4%, p = .035). After a median follow-up of 12.2 months, 154/225 (68.4%) of patients were free from atrial arrhythmia recurrence without ADT, which was higher in AI group compared with CF group, but without significant difference (71.1% vs. 63.2%, p = .253). The incidence of peri-procedural complications is low and without difference between two groups.

Conclusions: AI-guided ablation provided higher acute efficacy than CF-guided ablation in PV isolation for patients with paroxysmal AF. The long-term success rate in AI group was higher than CF group, but did not reach statistical significance.

Keywords: ablation index; atrial fibrillation; catheter ablation; contact force; radiofrequency ablation.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Anti-Arrhythmia Agents
  • Atrial Fibrillation* / surgery
  • Catheter Ablation*
  • Humans
  • Pulmonary Veins* / surgery
  • Radiofrequency Ablation*
  • Recurrence
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents